New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Pediatric multicenter study shows targeted therapy for high-risk Hodgkin lymphoma reduces relapse

Pediatric multicenter study shows targeted therapy for high-risk Hodgkin lymphoma reduces relapse

byEmory UniversityHodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0A targeted therapy for children with high-risk Hodgkin l
Oncology December 21,2023
Pediatric multicenter study shows targeted therapy for high-risk Hodgkin lymphoma reduces relapse

Pediatric multicenter study shows targeted therapy for high-risk Hodgkin lymphoma reduces relapse

byEmory UniversityHodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0A targeted therapy for children with high-risk Hodgkin l
Oncology December 21,2023
Multi-center study sheds light on understudied breast cancer type

Multi-center study sheds light on understudied breast cancer type

byUniversity of PittsburghCredit: Pixabay/CC0 Public DomainA multi-center analysis of patients with invasive lobular carcinoma, or ILC—the second most common histological subtype of invasive bre
Oncology December 21,2023
Multi-center study sheds light on understudied breast cancer type

Multi-center study sheds light on understudied breast cancer type

byUniversity of PittsburghCredit: Pixabay/CC0 Public DomainA multi-center analysis of patients with invasive lobular carcinoma, or ILC—the second most common histological subtype of invasive bre
Oncology December 21,2023
Diversity is everyone's responsibility: Researchers outline a path to representation in cancer clinical trials

Diversity is everyone's responsibility: Researchers outline a path to representation in cancer clinical trials

byAmerican Society of HematologyCredit: CC0 Public DomainA new study published today inBlood Advancesoutlines practical strategies for promoting diversity, equity, inclusion, and acc
Oncology December 21,2023
Diversity is everyone's responsibility: Researchers outline a path to representation in cancer clinical trials

Diversity is everyone's responsibility: Researchers outline a path to representation in cancer clinical trials

byAmerican Society of HematologyCredit: CC0 Public DomainA new study published today inBlood Advancesoutlines practical strategies for promoting diversity, equity, inclusion, and acc
Oncology December 21,2023
Multisite multiomic analysis reveals diverse resistance mechanisms in end-stage ovarian cancer

Multisite multiomic analysis reveals diverse resistance mechanisms in end-stage ovarian cancer

by Justin Jackson , Medical XpressThe clinical journey is shown for each patient, in 100 day intervals (x-axis), with the first tick referring to the day of first diagnostic information (surgery or CA
Oncology December 21,2023
Multisite multiomic analysis reveals diverse resistance mechanisms in end-stage ovarian cancer

Multisite multiomic analysis reveals diverse resistance mechanisms in end-stage ovarian cancer

by Justin Jackson , Medical XpressThe clinical journey is shown for each patient, in 100 day intervals (x-axis), with the first tick referring to the day of first diagnostic information (surgery or CA
Oncology December 21,2023
Multimodal sequencing achieves high-quality results from small volumes of frozen tumor specimens

Multimodal sequencing achieves high-quality results from small volumes of frozen tumor specimens

byColumbia University School of Engineering and Applied ScienceA Circos plot representing the results of matched T-cell receptor sequencing collected on a patient undergoing anti-PD1 therapy. Co
Oncology December 21,2023
Multimodal sequencing achieves high-quality results from small volumes of frozen tumor specimens

Multimodal sequencing achieves high-quality results from small volumes of frozen tumor specimens

byColumbia University School of Engineering and Applied ScienceA Circos plot representing the results of matched T-cell receptor sequencing collected on a patient undergoing anti-PD1 therapy. Co
Oncology December 21,2023
Polygenic risk scores may miss the mark when predicting aggressive prostate cancers

Polygenic risk scores may miss the mark when predicting aggressive prostate cancers

by Justin Jackson , Medical XpressCredit: Pixabay/CC0 Public DomainAccording to a research letter published inJAMA Internal Medicine, prostate cancer screening frequently results in biopsies tha
Oncology December 21,2023
Polygenic risk scores may miss the mark when predicting aggressive prostate cancers

Polygenic risk scores may miss the mark when predicting aggressive prostate cancers

by Justin Jackson , Medical XpressCredit: Pixabay/CC0 Public DomainAccording to a research letter published inJAMA Internal Medicine, prostate cancer screening frequently results in biopsies tha
Oncology December 21,2023
Significant treatment attrition rate seen in multiple myeloma

Significant treatment attrition rate seen in multiple myeloma

by Elana GotkineThere is a significant treatment attrition rate in newly diagnosed multiple myeloma (NDMM), according to a study published in the November issue ofLeukemia & Lymphoma.Victor
Oncology December 21,2023
Significant treatment attrition rate seen in multiple myeloma

Significant treatment attrition rate seen in multiple myeloma

by Elana GotkineThere is a significant treatment attrition rate in newly diagnosed multiple myeloma (NDMM), according to a study published in the November issue ofLeukemia & Lymphoma.Victor
Oncology December 21,2023
Multicancer early detection feasible for outpatients

Multicancer early detection feasible for outpatients

A blood-based multicancer early detection (MCED) test using cell-free DNA (cfDNA) is feasible for outpatients and has a positive predictive value of about 40 percent, according to a study presented at
Oncology December 21,2023
Multicancer early detection feasible for outpatients

Multicancer early detection feasible for outpatients

A blood-based multicancer early detection (MCED) test using cell-free DNA (cfDNA) is feasible for outpatients and has a positive predictive value of about 40 percent, according to a study presented at
Oncology December 21,2023
Genetic analysis of the most common type of bladder cancer yields guidance on treatment options

Genetic analysis of the most common type of bladder cancer yields guidance on treatment options

byUNC Lineberger Comprehensive Cancer CenterUC-GENOME study design and molecular subtyping shows enrichment of Stroma-rich primary tumors in metastatic datasets. Credit:Nature Communicatio
Oncology December 21,2023
Genetic analysis of the most common type of bladder cancer yields guidance on treatment options

Genetic analysis of the most common type of bladder cancer yields guidance on treatment options

byUNC Lineberger Comprehensive Cancer CenterUC-GENOME study design and molecular subtyping shows enrichment of Stroma-rich primary tumors in metastatic datasets. Credit:Nature Communicatio
Oncology December 21,2023
Longest follow-up of patients with early breast cancer shows radiotherapy does not improve survival after 30 years

Longest follow-up of patients with early breast cancer shows radiotherapy does not improve survival after 30 years

by European Organisation for Research and Treatment of CancerCredit: Unsplash/CC0 Public DomainRadiotherapy after breast-conserving surgery in conjunction with chemotherapy or tamoxifen to treat early
Oncology December 21,2023
Longest follow-up of patients with early breast cancer shows radiotherapy does not improve survival after 30 years

Longest follow-up of patients with early breast cancer shows radiotherapy does not improve survival after 30 years

by European Organisation for Research and Treatment of CancerCredit: Unsplash/CC0 Public DomainRadiotherapy after breast-conserving surgery in conjunction with chemotherapy or tamoxifen to treat early
Oncology December 21,2023
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com